Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA5A | P35218 | 3/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874978 | 1.00 | HSD11B1 (0.43) | HSD11B1CA1CA2CA9CA5A | |
| SCHEMBL883461 | 0.82 | TSHR (0.39) | CA1CA2CA9CA5AF2 | |
| SCHEMBL874727 | 0.82 | TSHR (0.39) | CA1CA2CA9CA5AF2 | |
| SCHEMBL2301608 | 0.77 | HSD11B1 (0.50) | HSD11B1CA1CA2CA9CA5A | |
| SCHEMBL10051833 | 0.77 | HSD11B1 (0.50) | HSD11B1CA1CA2CA9CA5A | |
| SCHEMBL2820587 | 0.75 | HPGD (0.57) | F2PRSS1PRSS2PRSS3KMT2A | |
| SCHEMBL2302403 | 0.75 | HSD11B1 (0.48) | HSD11B1CA1CA2CA9CA5A | |
| SCHEMBL2148897 | 0.69 | CA2 (0.53) | CA1CA2CA9CA5AF2 | |
| SCHEMBL875936 | 0.69 | NAMPT (0.38) | CA1CA2NAMPTKCNJ1EPHX1 | |
| SCHEMBL875937 | 0.69 | NAMPT (0.38) | CA1CA2NAMPTKCNJ1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359306-B2 | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9359306-B2 | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-20130245261-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245261-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| WO-2012038411-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245261-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | CDK1, CDK9, CDK6 | HSD11B1 895/4885CA1 2927/4885CA2 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.